Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of clonal hematopoiesis on tumor control following radiation therapy
    Meeting Abstract

    Tao, J.; Setton, J.; Vela, P. S.; Safonov, A. M.; Comen, E. A.; Braunstein, L. Z.; Reis-Filho, J. S.; Riaz, N.; Powell, S. N.; Levine, R. L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy (SELECT AML-1)
    Meeting Abstract

    Stein, E.; De Botton, S.; Pigneux, A.; McMahon, C.; Ball, B.; Borthakur, G.; Eghtedar, A.; Kambhampati, S.; Tache, J.; Wang, E. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy
    Meeting Abstract

    Sallman, D. A.; Foran, J. M.; Watts, J. M.; Stein, E.; De Botton, S.; Fathi, A. T.; Prince, G. T.; Stone, R. M.; Patel, P. A.; Roboz, G. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update
    Meeting Abstract

    Rea, D.; Mauro, M. J.; Hochhaus, A.; Boquimpani, C.; Lomaia, E.; Voloshin, S.; Turkina, A. G.; Kim, D. W.; Apperley, J.; Cortes, J. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms
    Meeting Abstract

    Rampal, R.; Ramanathan, S.; Papayannidis, C.; von Bubnoff, N.; Díaz, M. D. T.; Vidriales, M. B.; Burguera, A. D. L. F.; Masarova, L.; Al-Ali, H. K.; Lavie, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated acute myeloid leukemia ≥ age 60 years: Phase 1b interim results
    Meeting Abstract

    Mims, A. S.; Huang, Y.; Eisenmann, E.; Buelow, D.; Swords, R. T.; Foster, M. C.; Lin, T. L.; Baer, M. R.; Kovacsovics, T.; Al-Mansour, Z.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies
    Meeting Abstract

    Mato, A.; Danilov, A. V.; Patel, M. R.; Tees, M. T.; Flinn, I. W.; Ai, W. Z.; Patel, K.; Wang, M.; O'Brien, S. M.; Nandakumar, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial
    Meeting Abstract

    De Botton, S.; Risueño, A.; Schuh, A. C.; Lowenberg, B.; Kim, H. J.; Vyas, P.; Wei, A. H.; Stein, E. M.; Dohner, H.; Fathi, A. T.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial
    Meeting Abstract

    Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; García-Gutierrez, V.; Mauro, M. J.; Leip, E.; Purcell, S.; Viqueira, A.; Brümmendorf, T. H.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save